Mitral valve regurgitation

Mitral valve regurgitation (MVR) is a condition in which the mitral valve fails to close completely, resulting in backflow of blood from the left ventricle to the left atrium during systole. This condition can be either acquired or congenital, and is often accompanied by clinical manifestations of heart failure, shortness of breath, fatigue, and other symptoms. MVR is one of the most common cardiovascular pathologies at the intersection of cardiology and surgery. The condition requires careful monitoring and, in some cases, surgical intervention for correction. In this article, we will consider the main aspects of mitral valve regurgitation, including its history, epidemiology, genetic predisposition, risks of occurrence, diagnostic methods, treatment and monitoring of the disease, as well as age-related features of the disease.

History of the disease and interesting historical facts

The first mentions of heart disease can be found in the works of Hippocrates, but the systematization of information about the mitral valve began in the 16th-17th centuries, when anatomists and doctors were able to study the structure of the heart in detail. In 1893, German cardiologist Walter Landolt was the first to describe the clinical manifestations of mitral regurgitation using auscultation, which was an important step in diagnosis. Over time, imaging techniques such as echocardiography have significantly developed, allowing cardiologists to better understand the mechanisms of the disease and more effectively diagnose mitral regurgitation.

Epidemiology

According to modern studies, the prevalence of mitral valve regurgitation varies from 2% to 10% in the general population, while in the elderly this figure can reach 10-15%. Studies show that mitral regurgitation is one of the most common causes of hospitalization for cardiovascular diseases, often leads to the need for surgical intervention, and is associated with high morbidity and mortality.

Genetic predisposition to this disease

There is evidence of a genetic predisposition to mitral valve regurgitation, including mutations affecting connective tissue. For example, predisposing genes such as FBN1, responsible for the synthesis of the fibrillin anchoring protein, may play a key role in the development of mitral valve abnormalities. In addition, other genes associated with cardiomyopathy may also contribute to the development of MR. Studies show that hereditary predisposition is observed in families with Marfan syndrome and other connective tissue diseases.

Risk factors for the development of this disease

Mitral valve regurgitation can occur due to various risk factors, which include:

• Congenital anomalies of the mitral valve.
• Rheumatic fever and its consequences.
• Degenerative changes in connective tissues, such as Marfan syndrome.
• Aortic stenosis and other associated cardiovascular diseases.
• Age-related changes leading to calcification of the valves.
• Arterial hypertension, which contributes to cardiac overload.
• InfectiousEndocarditis, which can lead to damage to the valves.

Each of these factors can significantly increase the risk of developing mitral valve disease, often by affecting the structure and functionality of the mitral valve.

Diagnosis of this disease

Diagnosis of mitral valve regurgitation requires a comprehensive approach and includes:

• Clinical symptoms such as shortness of breath, weakness and edema.
• Auscultation to detect characteristic systolic murmur.
• Echocardiography as the primary imaging method for assessing the degree of regurgitation and valve condition.
• Doppler examination to assess hemodynamics and blood flow direction.
• Radiological tests, such as a chest x-ray, to assess the size of the heart.
• ECG to detect possible rhythm disturbances and myocardial hypertrophy.
• Differential diagnosis with other forms of heart failure and valve pathologies.

Treatment

Treatment of mitral valve regurgitation should be individualized and depends on the severity of the disease and the presence of symptoms. Depending on the clinical situation, the following are used:

• Monitoring patients with mild regurgitation.
• Pharmacologic therapy to manage symptoms of heart failure, including diuretics and ACE inhibitors.
• Surgery, such as annuloplasty or mitral valve replacement, for severe regurgitation.
• Use of minimally invasive technologies such as catheter ablation or transcatheter valve replacement.
• Rehabilitation measures including physical therapy and lifestyle modifications.

List of medications used to treat this disease

The main drugs used to treat RMC include:

• Angiotensin-converting enzyme inhibitors (eg, enalapril).
• Beta-blockers (eg, metoprolol).
• Diuretics (eg, furosemide) to control symptoms of heart failure.
• Antiarrhythmic drugs to control heart rhythm.
• Anticoagulants in case of atrial fibrillation.

Disease monitoring

Monitoring of patients with mitral valve regurgitation includes regular tests such as:

• Routine echocardiography to assess the dynamics of valve status.
• Assessment of clinical symptoms and their dynamics.
• ECG conductivity for arrhythmia risk assessment.
• Conducting laboratory tests to monitor concomitant diseases.

The prognosis for patients depends on the degree of regurgitation, clinical picture, presence of concomitant diseases and effectiveness of the treatment. Some patients may experience serious complications such as heart failure and arrhythmia.

Age-related features of the disease

Mitral valve regurgitation is more often diagnosed in older people, but it also occurs in young people, especially in the presence of congenital anomalies. Older patients have a more severe course of the disease, due to concomitant chronic pathologies. In young patients, mitral valve regurgitation may be associated with congenital defects and, as a rule, manifests itself with milder symptoms and a better prognosis. However, with age, the risk of disease progression increases significantly.

Questions and Answers

• What is mitral valve regurgitation? Mitral valve regurgitation is a pathological condition in which the mitral valve does not close completely, resulting in backflow of blood into the left atrium during systole.
• What are the main causes of this disease? Major causes include congenital anomalies, rheumatic fever, age-related changes in valves, hypertension, and infective endocarditis.
• What are the symptoms of mitral valve regurgitation? Symptoms may include shortness of breath, fatigue, foul-smelling cough, edema, and heart murmurs on auscultation.
• How is this disease diagnosed? Diagnosis includes echocardiography, auscultation, ECG and radiologic studies, as well as assessment of the patient's symptoms.
• How is mitral valve regurgitation treated? Treatment may include observation, pharmacologic therapy, surgery, and rehabilitation measures.